{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T01:06:13Z","timestamp":1648861573067},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.amjcard.2015.04.048","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T12:07:53Z","timestamp":1431086873000},"page":"350-354","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complex Disease, Partial Revascularization, and Adverse Outcomes in Patients Treated With Long-Term Warfarin Therapy Who Underwent Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"116","author":[{"given":"Khaled","family":"Yazji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorayya","family":"Kakhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Ossei-Gerning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Kinnaird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2015.04.048_bib1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary","volume":"4","author":"Faxon","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2015.04.048_bib2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.04.048_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ahj.2014.01.005","volume":"167","author":"Fiedler","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2015.04.048_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2015.04.048_bib5","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.04.048_bib6","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A\u00a0risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/2048872612453924","article-title":"Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome","volume":"1","author":"Abu-Assi","year":"2012","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.amjcard.2015.04.048_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.04.048_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1540-8183.2011.00683.x","article-title":"The management of patients on oral anticoagulation undergoing coronary stent implantation: a survey among interventional cardiologists from eight European countries","volume":"25","author":"Rubboli","year":"2012","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib10","first-page":"563","article-title":"Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry","volume":"26","author":"Rubboli","year":"2014","journal-title":"J\u00a0Invasive Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2014.03.060","article-title":"Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"114","author":"Goto","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ahj.2007.09.003","article-title":"Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry","volume":"155","author":"Wang","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2015.04.048_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCINTERVENTIONS.112.968792","article-title":"Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?","volume":"5","author":"Ruiz-Nodar","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2015.04.048_bib14","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"Antman","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib15","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.04.048_bib16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jacc.2012.11.049","article-title":"Why are we still using coronary bare-metal stents?","volume":"61","author":"Morice","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.113.001803","article-title":"Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score","volume":"128","author":"Farooq","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.04.048_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"\u201cTriple therapy\u201d rather than \u201ctriple threat\u201d: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2015.04.048_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.04.048_bib20","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","article-title":"Stent thrombosis after drug eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period","volume":"30","author":"Schulz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.04.048_bib21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.04.048_bib22","unstructured":"A study exploring two strategies of Rivaroxaban (JNJ39039039; BAY-59\u20137939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous intervention. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01830543. Accessed on May 28, 2015."},{"key":"10.1016\/j.amjcard.2015.04.048_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ahj.2013.01.008","article-title":"Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the BioFreedom drug-coated stent vs. the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy","volume":"165","author":"Urban","year":"2013","journal-title":"Am Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915012461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915012461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T15:27:52Z","timestamp":1537630072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914915012461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0002914915012461"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.04.048","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex Disease, Partial Revascularization, and Adverse Outcomes in Patients Treated With Long-Term Warfarin Therapy Who Underwent Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}